Chen J, Wang J, Schwab L, Park K, Seagroves T, Jennings L, Miller D, Li W. Novel benzimidazole analogs as potent HIF-1α inhibitors: biological evaluation, profiling drug-like properties, and biotransformation. Anticancer Research 2014. In press.
Lin Z, Yang R, Guan Z, Chen A, Li W. UPLC separation and QTof-MS identification of major alkaloids in plumula nelumbinis. Phytochemical Analysis 2014. In press.
Chen J, Wang J, Kim T, Tieu EW, Tang E, Lin Z, Kovacic D, Miller D, Postlethwaite A, Tuckey R, Slominski A, Li W. Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity. Anticancer Research 2014; 34(5):2153-2163.
Slominski A, Kim T,Takeda Y, Janjetovic Z, Brozyna A, Skobowiat C, Wang J, Postlethwaite A, Li W,Tuckey R, Jetten A. RORα and RORγ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxy-vitamin D. FASEB J 2014; 28(7):2775-2789.
Li W, Moore B. The effect of arvanil on prostate cancer cells studied by whole cell high resolution magic angle spinning NMR. Modern Chemistry & Applications 2014; 2(1):119.
Wang J, Li W. Discovery of novel SMAC mimetics as selective IAP inhibitors. J. Pharm Exp Ther 2014; 349(2):319-29.
Slominski A, Kim T, Shehabi H, Tang E, Benson H, Semak I, Lin Z, Yates C, Wang J, Li W, Tuckey R. In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland. Molecular and Cellular Endocrinology 2014; 383: 181-192.
Wang J, Chen J, Miller D, Li W. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Molecular Cancer Therapeutics 2014;13(1):16-26. This article is featured in Highlights of this issue.